A NEW GENERATION OF BIOLOGICS
Modalities
New modalities, such as viral vectors and mRNA, are critical in addressing challenging targets in bioprocessing. In addition to mAbs and rProteins, these exciting and potent clinical modalities promise faster, more efficient therapeutics with a broad range of potential applications.
In addition to therapeutic proteins, new biological targets include gene therapy, viral vectors, mRNA, and whole cells. The new modalities rely on critical raw material delivery systems such as pDNA, and viral vectors such as AAV, adenovirus, lentivirus, retrovirus, exosomes, oncolytic virus, and virus-based vaccines. Emerging modalities focus on whole cell bioprocessing such as cultured meat, and therapies based on stem cells, cell therapy, and T cells.
Repligen solutions help overcome key challenges in the development and production of these modalities into a new class of drugs. Repligen also offers hands-on process and implementation consultation from global Field Applications Specialists, and recognized gene therapy, oncolytic and vaccines industry experts.
Antibodies, rProteins
Therapeutic proteins treat a wide variety of clinical indications, including cancers, autoimmunity, inflammation, infectious disease and genetic disorders. Applications include the bioprocessing of monoclonal antibodies, antibody fragments, Fc and albumin fusions, blood factors, and protein-based vaccines.
Viral Vectors
Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, lentivirus, retrovirus, oncolytic virus, and virus-based vaccines.
mRNA
With the proven success of mRNA-based vaccines in addressing the COVID-19 pandemic, mRNA technology is at the forefront of transforming the world of medicine. Clinical trials are ongoing to develop both vaccines and therapies to treat infectious diseases and even cancer.
pDNA
Plasmid DNA (pDNA) is a critical raw material delivery template for the development and production of mRNA or viral vectors such as lentivirus and adeno-associated virus (AAV) vectors.
Antibody Drug Conjugates
Antibody-drug conjugates (ADC) represent a breakthrough in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. By delivering powerful treatments directly to cancer cells, ADCs provide an alternative solution that enhances efficacy and minimizes side effects.
Enabling Advanced Bioprocessing
From established biologics to emerging platforms, today's therapeutic modalities are transforming disease treatment. Repligen solutions are designed to help you overcome process challenges and drive the production of innovative therapies across a broad range of modalities, powering precision oncology, cell and gene therapies, and more.
